Pierfausto Seneci received a degree in Chemistry in Pavia, in 1983, and was then a postdoc at Politecnico di Milano. In 1986, he joined Lepetit (Gerenzano, I), working on natural products. In 1992, he joined Marion Merrell Dow (Strasbourg, F), working on neurodegenerative diseases. In 1995, he joined Selectide (Tucson, Arizona), synthesizing natural-product-like libraries. In 1996, he joined SmithKlineBeecham (Rennes, F) as Head of Medicinal Chemistry, working in oncology and osteoporosis. In 1997, he joined GlaxoWellcome (Verona, I) as Director of Lead Discovery, responsible for antibacterial and CNS projects. In 2000, he was a Founder of biotech NADAG (Munich, D), where he led efforts to cure Alzheimer's disease; in 2003, he became the CEO, and he merged NADAG with Sireen AG to give Sirenade Pharma, securing financing and licensing in CNS/neurodegeneration. In late 2002, he became an Associate Professor at the University of Milan, where he taught basic and advanced courses, and led projects in CNS and oncology. Since 2005, he has assisted Italian and European companies as a business development–strategic consultant. Between 1997 and 2009, he was a Scientific Advisor for UNIDO, to facilitate technology transfer to developing countries. Since 2009, he has acted as an expert to evaluate projects and companies for the EC, the “Regione Lazio”, “Regione Puglia”, “Regione Sardegna” and MIUR-Italy. He is the author of four books, more than 120 scientific papers, and 15 patents.